MindWalk Holdings Corp. Common Stock (HYFT) Stock
Key stats
- Market cap
- $49.00M
- Price / Earnings ratio
- -3.9x
- EPS (TTM)
- -$0.26
- Volume
- Loading
- 52-week high
- $2.99
- 52-week low
- $0.97
Source: third-party data provider, as of November 13, 2026
Compare with HYFT
Recent news

MindWalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp. Announces Leadership Update
HYFT

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
HYFT

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
HYFT

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
HYFT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.24
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.01
- SMA 50
- $1.29
- Price below SMA 50
- EMA 50
- $1.25
- Price below EMA 50
- SMA 200
- $1.35
- Price below SMA 200
- EMA 200
- $1.42
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

MindWalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp. Announces Leadership Update
HYFT

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
HYFT

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
HYFT

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
HYFT

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
HYFT

MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
HYFT

MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
HYFT

MindWalk Q1 Earnings Call Highlights
MindWalk Q1 Earnings Call Highlights
HYFT

MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
HYFT

MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
HYFT
News tone: automated (AI) classification of the article's content, not a price prediction.
About MindWalk Holdings Corp. Common Stock
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jennifer Lynne Bath Ph.D. | CEO, President & Non-Independent Director | — |
| Mr. Richard Scott Areglado | Chief Financial Officer | 1964 |
| Dr. Thomas Lynch Ph.D. | Chief Business Officer | — |
| Ms. Kari Graber | Vice President of Commercial Services | — |
| Dr. Shuji Sato | Vice President of Innovative Solutions | — |
| Mr. Dirk Van Hyfte M.D., Ph.D. | Chief Technology Officer | — |
| Mr. Frederic Chabot | Head of Corporate Development | — |
| Ms. Ingrid Brands M.D., Ph.D. | Chief Innovation & Strategy Officer | — |
| Ms. Lori Anderson | Vice President of Brand Marketing and Creative | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 35.24
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.01
- SMA 50
- $1.29
- Price below SMA 50
- EMA 50
- $1.25
- Price below EMA 50
- SMA 200
- $1.35
- Price below SMA 200
- EMA 200
- $1.42
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -12.1 | +5.1 | +17.0 | -0.5 | ||||||||
| 2026 | -19.8 | -30.2 | -0.9 | +4.4 | +45.5 | -9.2 | -20.4 | -0.7 | +2.3 | -15.0 | -6.4 |



